Valuation Theralase Technologies Inc.
Stocks
TLT
CA88337V1004
Advanced Medical Equipment & Technology
|
Market Closed -
Toronto S.E.
23:15:52 06/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.1900 CAD | 0.00% |
|
+5.56% | +15.15% |
| 10-26 | Theralase® Technologies Inc. Provides Bladder Cancer Clinical Study Update and Oncology Pipeline Expansion | CI |
| 09-15 | Theralase Technologies Commences GLP Toxicology Analysis of Rutherrin | CI |
Company Valuation: Theralase Technologies Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 76.6 | 69.28 | 39.98 | 65.66 | 43.71 | 58.99 | - | - |
| Change | - | -9.56% | -42.29% | 64.23% | -33.43% | 34.96% | - | - |
| Enterprise Value (EV) | 76.6 | 69.28 | 39.98 | 65.66 | 43.71 | 58.99 | 58.99 | 58.99 |
| Change | - | -9.56% | -42.29% | 64.23% | -33.43% | 34.96% | 0% | 0% |
| P/E | -17x | -12.8x | -7.95x | -14.7x | -10.3x | -19x | 9.5x | 3.8x |
| PBR | 15.1x | 21.5x | 17.5x | 31.9x | 23.5x | 6.33x | 3.8x | 1.73x |
| PEG | - | -0.9x | 0.7x | 0.8x | 0.9x | 0.5x | -0x | 0x |
| Capitalization / Revenue | 98.1x | 60.8x | 37.4x | 63.5x | 53.5x | 75.1x | 1.74x | 0.79x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 75.1x | 1.74x | 0.79x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.022 | -0.025 | -0.022 | -0.018 | -0.016 | -0.01 | 0.02 | 0.05 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.7806 | 1.139 | 1.07 | 1.033 | 0.8165 | 0.786 | 33.89 | 74.69 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - | - |
| Net income 1 | -4.411 | -5.235 | -4.571 | -4.256 | -4.121 | -4.124 | 6.901 | 20.1 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 0.3750 | 0.3200 | 0.1750 | 0.2650 | 0.1650 | 0.1900 | 0.1900 | 0.1900 |
| Nbr of stocks (in thousands) | 204,276 | 216,503 | 228,461 | 247,780 | 264,909 | 310,483 | - | - |
| Announcement Date | 4/29/22 A | 4/26/23 A | 3/27/24 A | 3/12/25 A | 5/4/26 A | - | - | - |
1CAD in Million2CAD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| -19x | - | - | - | 41.85M | ||
| 34.66x | 5.93x | 22.65x | 0.27% | 257B | ||
| 53.97x | 13.11x | 28.13x | -.--% | 157B | ||
| 35.98x | 6.85x | 21.44x | 0.64% | 162B | ||
| 18.26x | 3.59x | 11.7x | -.--% | 61.96B | ||
| 39.97x | 8.04x | 25.42x | -.--% | 58.73B | ||
| 22.04x | 2.61x | 13.16x | 2.29% | 55.42B | ||
| 47.48x | 11.69x | 25.77x | -.--% | 49.18B | ||
| 33.47x | 6.63x | 22.53x | 0.6% | 49.27B | ||
| 110.61x | 7.51x | 22.85x | -.--% | 44.96B | ||
| Average | 37.74x | 7.33x | 21.52x | 0.42% | 89.59B | |
| Weighted average by Cap. | 41.16x | 7.56x | 22.41x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- TLT Stock
- Valuation Theralase Technologies Inc.
Select your edition
All financial news and data tailored to specific country editions
















